) vaccines division, Sanofi Pasteur, recently announced that
Cdiffense, a phase III program, has been initiated. Sanofi is
working on developing a vaccine for the prevention of primary
symptomatic clostridium difficile infection (CDI). The program
aims to assess the safety, efficacy and immunogenicity of the CDI
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
In Canada, Sanofi has started enrolling volunteers for the
randomized, observer-blind, placebo-controlled, multi-center,
multi-national (across 17 countries), phase III trial. The trial
will enroll up to 15,000 volunteers aged ≥ 50 years, who have
received systemic antibiotics in the past year and are planning
to be hospitalized or were hospitalized at least twice before.
Earlier this year, Sanofi's vaccine portfolio received a boost
when the European Commission approved its 6-in-1 pediatric
vaccine Hexyon/Hexacima (DTaP-IPV-Hib-HepBvaccine).
The 6-in-1 vaccine is indicated for the prevention of diphtheria,
tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis
and invasive infections caused by haemophilus influenzaetype b in
We note that Sanofi possesses one of the world's leading vaccine
operations, with total sales of €3.9 billion in 2012. The
company's portfolio includes pediatric vaccines, influenza
vaccines, adult and adolescent booster vaccines, meningitis
vaccines, and travel and endemic vaccines. Sanofi also has a
strong position in both seasonal and pre-pandemic influenza
vaccines. Sanofi continues to expand its vaccine business. We
expect a significant ramp in vaccine sales over the next several
Sanofi carries a Zacks Rank #5 (Strong Sell). We are concerned
about generic erosion confronting most of Sanofi's key drugs.
Additionally, recent pipeline failures (oncology candidate
- iniparib and anticoagulant - otamixaban) have put immense
pressure on Sanofi's pipeline.
At present, companies like
Gilead Sciences, Inc.
) look well-positioned with all three being Zacks Rank #1 (Strong